Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy

American Journal of Surgery

Volumn 210, Issue 1, 2015, Pages 15-23

  Luc, Guillaume ^a   Gersen Cherdieu, Hélène ^a   Degrandi, Olivier ^a   Terrebonne, Eric ^a   Chiche, Laurence ^a   Collet, Denis ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Gastroesophageal adenocarcinoma; Perioperative chemotherapy; Postoperative chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; LENGTH OF STAY; LOCALLY ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEX RATIO; STOMACH CARCINOMA; SURGICAL MORTALITY; VERY ELDERLY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ESOPHAGEAL NEOPLASMS; EVALUATION STUDY; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84937191872     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2014.12.036     Document Type: Article

References (19)

1. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. J.R. Siewert, M. Feith, and M. Werner Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients Ann Surg 232 2000 353 361
3. D. Cunningham, W.H. Allum, and S.P. Stenning Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
4. M. Ychou, V. Boige, and J.P. Pignon Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial J Clin Oncol 29 2011 1715 1721
5. A.M. Reece-Smith, S. Saha, and M.L. Cunnell MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastroesophageal adenocarcinomas J Surg Oncol 106 2012 748 752
6. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
7. U. Ronellenfitsch, M. Schwarzbach, and R. Hofheinz Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus Cochrane Database Syst Rev 5 2013 CD008107
8. A. Mirza, S. Pritchard, and I. Welch The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas Int J Surg Oncol 2013 2013 781742
9. S.B. Edge, D.R. Byrd, and C.C. Compton AJCC Cancer Staging Manual 7th ed. 2010 Springer New York, NY
10. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
11. R. Diaz-Nieto, R. Orti-Rodriguez, and M. Winslet Post-surgical chemotherapy versus surgery alone for resectable gastric cancer Cochrane Database Syst Rev 9 2013 CD008415
12. S. Sakuramoto, M. Sasako, and T. Yamaguchi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820
13. M. Sasako, S. Sakuramoto, and H. Katai Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer J Clin Oncol 29 2011 4387 4393
14. S.Y. Moorcraft, E.C. Smyth, and D. Cunningham Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 18 2015 1 10
15. Y.J. Bang, Y.W. Kim, and H.K. Yang Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet 379 2012 315 321
16. S.H. Noh, S.R. Park, and H.-K. Yang Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial Ann Oncol 24 Suppl 4 2013 iv14
17. G. Luc, M. Durand, and L. Chiche Major post-operative complications predict long-term survival after esophagectomy in patients with adenocarcinoma of the esophagus World J Surg 39 2015 216 222
18. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 2001 539 545
19. A. Mantovani, P. Allavena, and A. Sica Cancer-related inflammation Nature 454 2008 436 444